MEDICAL

Thermo Fisher Scientific and Qatar Genome Program Partner to Advance Precision Medicine

Thermo Fisher Scientific | May 24, 2022

Thermo_Fisher_Scientific
Thermo Fisher Scientific, the world leader in serving science, and Qatar Genome Program (QGP), a member of Qatar Foundation (QF), have partnered with the goal of accelerating genomic research and clinical applications of predictive genomics in Qatar as a step toward expanding the benefits of precision medicine across Arab populations globally.

Under the agreement, Thermo Fisher and Qatar Genome Program will develop an Axiom* custom genotyping array for pan-Arab populations using whole genome sequencing data from 19 Arab countries. The array, with about 800,000 variants, aims to help drive scientific research and insights into conditions including diabetes, cardiovascular and metabolic diseases, autism, inherited genetic disorders and cancer. Once available through Thermo Fisher’s global commercial channels in late 2022, the array is intended to provide a cost-effective alternative to whole genome sequencing for Arab populations, enabling increased diversity in large genome-wide studies.

Qatar’s national vision is to provide a high standard of living for our people, and that includes providing access to genomics data, technology and insights to improve population health across the country, Our collaboration with Thermo Fisher will not only help us advance precision medicine in Qatar but also among people of Arab identity worldwide.”

Dr. Radja Badji, genome operations manager at Qatar Genome Program.

Thermo Fisher began working with Qatar Genome Program in 2018 to establish the first microarray designed specifically for the Qatari population. The Q-Chip detects genetic alterations that increase individuals’ risk of both prevalent and rare diseases. As part of the new agreement, the organizations will continue to refine algorithms and define clinically actionable content to assess polygenic risk scores, a measure of disease risk, and clinically relevant variants, including those related to pharmacogenomics.

Thermo Fisher’s Axiom microarray technology is designed to help accelerate precision medicine, and we are honored to partner with the Qatar Genome Program as they take bold steps to leverage the power of genomics to improve the standard of care for human health, Together, we’re creating building blocks for implementing comprehensive precision medicine initiatives at scale for population health.”

Chad Carter, vice president and general manager of microarray genetic solutions at Thermo Fisher Scientific.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

About the Qatar Genome Program
The Qatar Genome Program is an ambitious population-based project aimed at positioning Qatar among the pioneering countries in the implementation of precision medicine. Whole genome sequencing and other omics data is being combined with phenotypic data within the Qatar Biobank, providing a resource for breakthrough research discoveries and to help policy makers set future healthcare priorities for Qatar.

Spotlight

Environmental biotechnology is biotechnology that is applied to and used to study the natural environment. Environmental biotechnology could also imply that one try to harness biological process for commercial uses and exploitation.

Spotlight

Environmental biotechnology is biotechnology that is applied to and used to study the natural environment. Environmental biotechnology could also imply that one try to harness biological process for commercial uses and exploitation.

Related News

INDUSTRIAL IMPACT

Sartorius Stedim Biotech to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions

Sartorius Stedim Biotech | August 09, 2022

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has agreed to acquire 100 percent of Albumedix Ltd. from private investors. The Nottingham, UK-based company provides best-in-class recombinant albumin-based solutions. Recombinant human albumin is an important component for the biopharmaceutical industry required for various applications, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral therapies. The business, founded in 1984, has more than 100 employees and is expected to generate revenue of approximately £33 million in 2022 with a significant double-digit EBITDA margin. The agreed purchase price amounts to approximately £415 million. The transaction is subject to regulatory approval and is expected to close before the end of the third quarter of 2022. "Albumedix will be an important addition to Sartorius Stedim Biotech's advanced therapy solutions, particularly regarding our cell culture media business, as it will enable us to strengthen our position as a relevant supplier of innovative chemically defined media and critical ancillary materials. This market offers high growth potential due to the increasing regulatory requirements as well as rising demand for the use of recombinant human albumin in near-patient applications. Albumedix will also add important formulation excipients to our vaccine production solutions, allowing us to expand our existing customer relationships and forge new ones," René Fáber, member of the Board of Directors and Deputy CEO of Sartorius Stedim Biotech "We are delighted to be joining forces with Sartorius Stedim Biotech and look forward to accelerating our ambitious growth plans in delivering critical solutions to our global customers. We have been highly impressed with Sartorius Stedim Biotech's knowledge and capabilities in the bioprocessing markets, and we are excited to join this purposeful journey. We believe Sartorius Stedim Biotech will bring tremendous value in strengthening our market reach and broadening our innovation capacity, as well as significantly scaling up our existing platform. We remain focused on our promise of empowering excellence in the life science industry," said Jonas S. Møller, CEO of Albumedix. The existing 72,000-square-foot Albumedix site in Nottingham will be established as a center of excellence for innovation and GMP-compliant production of critical raw materials in Sartorius Stedim Biotech. Milbank LLP provided legal counsel to Sartorius Stedim Biotech in this transaction. William Blair acted as financial advisor to Albumedix, and Eversheds Sutherland provided legal counsel. This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. This is a translation of the original French-language press release. Sartorius Stedim Biotech shall not assume any liability for the correctness of this translation. The original French press release is the legally binding version. A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, the shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2021, the company employed more than 10,400 people, and earned sales revenue of around 2.89 billion euros.

Read More

MEDTECH

BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care

BeiGene | August 16, 2022

BeiGene a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide, today announced a strategic agreement with Ontada®, a McKesson business with leading provider technology and actionable real-world research, education, and evidence in oncology, to improve U.S. community oncology care through the development of real-world evidence data, tools, and insights to help increase access to affordable, cutting-edge therapies. The partnership will be led by Ontada and focus on accelerating the development and implementation of RWE to improve community education on the financial impact and value of oncolytics as well as improve patient access to oncology medicines. “BeiGene is excited to work with Ontada to advance our shared vision of improving patient access, affordability, and value for community oncology stakeholders and key partners working at the intersection of clinical practice and real-world evidence. Working together, BeiGene and Ontada will generate novel oncology insights through real-world data, tools, and technologies that will facilitate the acceleration of precise decision-making in support of community oncology practices whose ultimate mission is to improve patient outcomes.” Josh Neiman, Chief Commercial Officer, North America and Europe, at BeiGene As part of the collaboration, the companies will optimize the use of RWE to communicate value across key stakeholders including patients, providers, and payers; develop timely education on emerging science and therapeutic differentiation; and collaborate to advance use of RWE in healthcare and regulatory decision making to increase timely and affordable patient access to life-saving oncology therapies. “BeiGene aims to bring 10 molecules per year to the clinic starting in 2023 and, as this research advances, we’re delighted to form this strategic partnership with McKesson, which shares the same vision as BeiGene for improving the care of cancer patients,” said Christiane Langer, M.D., Senior Vice President of Global Medical Affairs, Ex-China, at BeiGene. “This collaboration will leverage Ontada’s technology platform and deep understanding of the experiences of patients treated in community oncology clinics to help accelerate both the development of the BeiGene portfolio and expand access to treatment options.” “As a leader in real-world research, Ontada is uniquely positioned to support complex research that uncovers deeper patient insights and perspectives that advance cancer care,” said Susan Shiff, Ph.D., president of Ontada. “We are excited to announce this unique partnership with BeiGene and look forward to developing a stronger understanding of how to better treat oncology patients through the use of real-world data and evidence.” About Ontada® Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer. Part of McKesson Corporation, Ontada was founded on the core belief that precise insights – delivered exactly at the point of need – can save more patients’ lives. We connect the full patient journey by combining technologies used by The US Oncology Network and other community oncology providers with real-world data and research relied on by all top 15 global life sciences companies. Our work helps accelerate innovation and power the future of cancer care. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories. BeiGene Oncology BeiGene is committed to advancing best- and first-in-class clinical candidates internally or with like-minded partners to develop impactful and affordable medicines for patients across the globe. We have a growing R&D and medical affairs team of approximately 2,900 colleagues dedicated to advancing more than 100 clinical trials that have involved more than 16,000 subjects. Our expansive portfolio is directed predominantly by our internal colleagues supporting clinical trials in more than 45 countries and regions. Hematology-oncology and solid tumor targeted therapies and immuno-oncology are key focus areas for the Company, with both mono- and combination therapies prioritized in our research and development. BeiGene currently has three approved medicines discovered and developed in our own labs: BTK inhibitor BRUKINSA® in the U.S., China, the European Union, Great Britain, Canada, Australia, and additional international markets; and the non-Fc-gamma receptor binding anti-PD-1 antibody, tislelizumab, as well as the PARP inhibitor, pamiparib, in China. BeiGene also partners with innovative companies who share our goal of developing therapies to address global health needs. We commercialize a range of oncology medicines in China licensed from Amgen, Bristol Myers Squibb, EUSA Pharma and Bio-Thera. We also plan to address greater areas of unmet need globally through our other collaborations including with Mirati Therapeutics, Seagen, and Zymeworks. In January 2021, BeiGene and Novartis announced a collaboration granting Novartis rights to co-develop, manufacture, and commercialize BeiGene’s anti-PD1 antibody, tislelizumab, in North America, Europe, and Japan. Building upon this productive collaboration, BeiGene and Novartis announced an option, collaboration, and license agreement in December 2021 for BeiGene’s TIGIT inhibitor, ociperlimab, that is in Phase 3 development. Novartis and BeiGene also entered into a strategic commercial agreement through which BeiGene will promote five approved Novartis Oncology products across designated regions of China. About BeiGene BeiGene is a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 8,500 colleagues spans five continents, with administrative offices in Beijing, China; Cambridge, U.S.; and Basel, Switzerland.

Read More

MEDTECH

BiOWiSH Technologies and SABIC Agri-Nutrients Company Announce Bio-Enhanced Mineral Fertilizer Collaboration

BiOWiSH Technologies, Inc. | July 22, 2022

BiOWiSH Technologies, Inc. and SABIC Agri-Nutrients Company announced the successful completion of a year-long technical evaluation of BiOWiSH® Crop Liquid technology coated on SABIC’s urea in nine countries across five continents and nine different crop types. BiOWiSH® Crop Liquid is a blend of proprietary microbial cultures that can be coated onto dry fertilizer or mixed with liquid fertilizers to create an enhanced efficiency fertilizer specifically designed to optimize yield potential and improve soil productivity. Featuring the company’s proprietary HoloGene 3™ technology, BiOWiSH® Crop Liquid creates a high-performance partnership between the plant and BiOWiSH microorganisms. The new alliance has a combined genetic profilethat enhances native microbial activity in the soil, promotes soil quality, and supports the plant’s natural ability to resist environmental stress. This optimizes crop yield potential by increasing nutrient availability and improving soil productivity and plant vigor. This unique mode of action, combined with the product’s industry-leading shelf life, is proven to achieve consistent desired results across a broad range of operating conditions, climates and environments – all at a low cost to farmers. “We are thrilled to confirm that SABIC AN Bio-Enhanced Urea powered by BiOWiSH® has performed extremely well in the field,” Munif Al-Munif, General Manager Agri-Nutrients Technology at SABIC AN “Our uniform, high-crushing strength urea combined with the superior technology of BiOWiSH® Crop Liquid delivers extended stability and consistent performance at a price per acre farmers can afford. In an industry challenged with high regulatory pressures and global food demand, we are excited to offer a sustainable product that safely increases crop production and generates higher profits for growers,” he added. The market launch of SABIC AN Enhanced Urea will initially be fulfilled through SABIC AN partners in select target countries while the teams work together to expand in other regions around the world. The launch follows extensive successful testing of the product across multiple international markets, including the United States. The Bio-Enhanced Urea, powered by BiOWiSH®, will be available at the same price as standard urea through the Archer-Daniels-Midland Company (ADM) and American Plant Food (APF) for a limited time in select areas. Customers can contact their ADM or APF representative for more details. In addition, SABIC AN and BiOWiSH have constructed a joint development platform designed to advance further customizations across a range of SABIC AN’s high-efficiency fertilizers. This partnership is the foundation for future products and other agronomic innovations. “We appreciate the close collaboration with SABIC AN’s team,” said BiOWiSH CEO Ian Edwards. “It is very exciting that a market-leading fertilizer company such as SABIC AN recognizes the importance of biologicals and is placing such high focus and energy on bringing Bio-Enhanced Mineral Fertilizer to customers across the globe. Together, we will work toward our shared goal of developing agricultural solutions that help farmers maximize productivity and increase income – while at the same time, improving environmental outcomes.” SABIC AN Bio-Enhanced Urea will be available to farmers in additional locations in the future, enabling growers to experience the benefits of BiOWiSH®-powered fertilizer. About BiOWiSH Technologies Headquartered in Cincinnati, Ohio, BiOWiSH Technologies, Inc. is a global provider of biotechnology solutions for the agriculture, aquaculture, and environmental management industries. As a leader in the agricultural market, we help farmers increase crop production sustainably, safely and cost effectively. Our revolutionary BiOWiSH® Crop Liquid can be coated onto dry fertilizer or mixed with liquid fertilizer to create an enhanced efficiency fertilizer that optimizes yield potential, expresses plant vigor and improves soil productivity across a broad range of operating conditions, climates and environments. By unifying nature and science, BiOWiSH reinvents the way food is grown. About SABIC Agri-Nutrients Company SABIC AN is a public joint stock company listed on the Saudi Stock Exchange where SABIC owns 50.1% with the remaining 49.9% being held by the private sector and the public. It is one of the leading global fertilizer producers. SABIC AN portfolio includes urea, ammonia, phosphate and other specialized products.

Read More